Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control

13 May 2021

Abstract excerpt

Synovial sarcoma is an aggressive malignancy with no effective treatments for patients with metastasis. The synovial sarcoma fusion SS18-SSX, which recruits the SWI/SNF-BAF chromatin remodeling and polycomb repressive complexes, results in epigenetic activation of FGF receptor (FGFR) signaling. In genetic FGFR-knockout models, culture, and xenograft synovial sarcoma models treated with the FGFR inhibitor BGJ398,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histiocytic Disorders and Treatments
Share to Sarcoma Diagnosis and Treatment
Share to Tumors and Oncological Cases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33983905
DOI: 10.1172/jci141908

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 13 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway controlPMID 33983905Read ↗

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcomaSemantic proximity Read ↗

VCAN is essential for ERK5-driven tumorigenesis in soft tissue sarcomaSemantic proximity Read ↗

Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcomaSemantic proximity Read ↗

Profiling potential targets of anlotinib in human synovial sarcoma patients and immunocompetent mouse modelsSemantic proximity Read ↗

Molecular Profiling Defines Three Subtypes of Synovial SarcomaSemantic proximity Read ↗

Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma CellsSemantic proximity Read ↗

Synovial Sarcoma Chromatin Dynamics Reveal a Continuum in SS18:SSX ReprogramingSemantic proximity Read ↗

Mapping chromatin state and transcriptional response in CIC-DUX4 undifferentiated round cell sarcomaSemantic proximity Read ↗

Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatmentSemantic proximity Read ↗

SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic ModifierSemantic proximity Read ↗

Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational ResearchSemantic proximity Read ↗

Synovial Sarcoma: Recent Discoveries as a Roadmap to New Avenues for TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.